60 In the phase 2a biomarker study, a nominally significant improvement in MMN and a statistical trend toward improvement for the ASSR were observed. 71 This result is consistent with enhanced NMDAR activity and suggests that luvadaxistat treatment has the potential to improve the auditory processing circuits that are impaired in schizophrenia. 72-74 Furthermore, this finding is reminiscent of the improvements in MMN observed with D-serine treatment, as described in Section 2.
← all excerpts
Therapeutic potential of D-amino acid oxidase inhibitors for cognitive impairment associated with schizophrenia: learnings from luvadaxistat.
1
—
—